Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …

Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …

Nonalcoholic fatty liver disease (NAFLD) is usually characterized with disrupted bile acid
(BA) homeostasis. However, the exact role of certain BA in NAFLD is poorly understood …

Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear
receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral …

Based on the assumption that characterizing the history of a disease will help in improving
practice while offering a clue to research, this article aims at reviewing the history of …

Background & Aims Peroxisome proliferator-activated receptors (PPARs) have been
implicated in non-alcoholic steatohepatitis (NASH) pathogenesis, mainly based on animal …

With nonalcoholic steatohepatitis (NASH), NASH cirrhosis, and NASH-related hepatocellular
carcinoma becoming increasingly prevalent, the need for effective therapies has never been …

Of all the aspects of non-alcoholic fatty liver disease (NAFLD), the slowest advances have
occurred in the therapeutic field. Thirty-five years after its formal description and after 15 …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western countries and is considered the hepatic manifestation of metabolic syndrome. The …

Steatosis of the liver may arise from a variety of conditions, but the molecular basis for lipid
droplet formation is poorly understood. Although a certain amount of lipid storage may even …